Tag: Atracurium

For non-emergency intubation, an intravenous bolus of atracurium typically provides adequate conditions for muscle relaxation within 2 to 2.5 minutes. Atracurium is an intermediate-acting neuromuscular blocking agent primarily used in surgical procedures and intensive care settings to facilitate medical interventions.

First approved for medical use in the United States in 1983, atracurium besylate is an intermediate-acting neuromuscular blocking agent. It is primarily used as an adjunct to general anesthesia to produce skeletal muscle relaxation, facilitate endotracheal intubation, and aid in mechanical ventilation in intensive care unit (ICU) patients.

Cisatracurium is predominantly cleared from the body through an organ-independent chemical process known as Hofmann elimination, a unique characteristic that differentiates it from many other neuromuscular blocking agents. This article explores how is cisatracurium cleared and the implications for its use in patients with compromised organ function.

Neuromuscular blocking agents (NMBAs) like atracurium are responsible for 60-70% of anaphylactic episodes during general anesthesia [1.10.2]. Understanding **what are the side effects of atracurium** is crucial for patient safety in perioperative settings.

While atracurium is an intermediate-acting neuromuscular blocker, its prolonged use, especially in the ICU, can lead to significant complications [1.2.6]. Understanding what are the prolonged effects of atracurium is critical for patient safety and optimizing recovery.

The incidence of atracurium-induced bronchospasm is reported to be between 0.2% and 1.5%. This adverse reaction, particularly concerning for patients with underlying respiratory conditions, hinges on a specific pharmacological mechanism that explains **how does atracurium cause bronchospasm**.

As a non-depolarizing neuromuscular blocking agent, atracurium is specifically designed to cause controlled, temporary paralysis during surgical procedures and mechanical ventilation. The critical question, 'Can atracurium cause paralysis?', is answered affirmatively by its fundamental pharmacology.